文献计量视角下的结核分枝杆菌潜伏感染研究现状与展望

doi:10.19982/j.issn.1000-6621.20240235

中国防痨杂志 ›› 2024, Vol. 46 ›› Issue (10): 1209-1218.doi: 10.19982/j.issn.1000-6621.20240235

文献计量视角下的结核分枝杆菌潜伏感染研究现状与展望

杨逸轩¹, 辛继宾²^,³, 阮巧玲¹, 应峻²^,³^,⁴, 张文宏¹()

¹国家传染病医学中心/复旦大学附属华山医院,上海 200040
²复旦大学图书馆,上海 200433
³复旦大学大健康信息研究中心,上海 200433
⁴复旦大学循证医学中心,上海 200032

收稿日期:2024-06-11 出版日期:2024-10-10 发布日期:2024-09-29
通信作者: 张文宏,Email:zhangwenhong@fudan.edu.cn E-mail:zhangwenhong@fudan.edu.cn
作者简介:注:辛继宾和杨逸轩对本文有同等贡献,为并列第一作者
基金资助:
国家自然科学基金面上项目(82271794);上海市加强公共卫生体系建设三年行动计划(GWVI-11.1-07)

Research status and future prospects of latent tuberculosis infection from a bibliometric perspective

Yang Yixuan¹, Xin Jibin²^,³, Ruan Qiaoling¹, Ying Jun²^,³^,⁴, Zhang Wenhong¹()

¹National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China
²Fudan University Library, Shanghai 200433, China
³Big Health Informatics Research Center, Fudan University, Shanghai 200433, China
⁴Evidence-Based Medicine Center, Fudan University, Shanghai 200032, China

Received:2024-06-11 Online:2024-10-10 Published:2024-09-29
Contact: Zhang Wenhong, Email: zhangwenhong@fudan.edu.cn E-mail:zhangwenhong@fudan.edu.cn
Supported by:
National Natural Science Foundation of China General Project(82271794);Three-Year Action Plan for Strengthening the Construction of Public Health System in Shanghai(GWVI-11.1-07)

摘要/Abstract

摘要：

目的：采用文献计量学方法对结核分枝杆菌潜伏感染研究近10年的相关文献进行分析,帮助研究人员了解该领域研究现状与趋势。方法：基于Web of Science核心合集数据库中科学引文索引扩展版,检索字段设定在主题,使用的关键词主要包括:“Latent Tuberculosis”或“Latent TB”或“LTBI”等。检索时间为2024年5月13日,文献的最终出版时间限定为2014—2023年,文献类型限定为原始研究性论文、综述,语言限定为英语,共获得相关文献4210篇。借助VOSviewer软件将结果可视化,从发文趋势、期刊分析、高被引论文分析、国际科研合作网络及关键词聚类等角度进行深入分析和讨论。结果：自世界卫生组织2015年提出结核分枝杆菌潜伏感染干预策略以来,话题持续获得全球学术界的关注,2014年1月至2023年12月共发表相关文献4210篇,总被引次数74324次,篇均被引次数17.65次;其中,美国发文量最多(1314篇,31.21%),其次是中国(587篇,13.94%)。国际科研合作网络分析结果显示,结核分枝杆菌潜伏感染领域研究形成了以美国、中国、英国、印度和意大利等为主体的国家间紧密合作;关键词聚类提示,结核分枝杆菌潜伏感染领域当前主要研究热点为:结核分枝杆菌潜伏感染的免疫机制、结核分枝杆菌潜伏感染的综合管理、结核分枝杆菌潜伏感染与风湿性疾病和结核分枝杆菌潜伏感染的筛查等。结论：本文揭示和讨论了结核分枝杆菌潜伏感染领域的研究现状及展望,可为该领域相关研究机构和学者提供一定借鉴和参考。

关键词: 分枝杆菌,结核, 感染, 文献计量学, 总结性报告(主题)

Abstract:

Objective: This study employs bibliometric analysis to examine the literature on latent tuberculosis infection (LTBI), with the goal of providing researchers with a comprehensive understanding of the current research landscape and future trends. Methods: The analysis was conducted using the expanded version of the Science Citation Index in the Web of Science Core Collection database, with the search field set to the topic. The primary keywords included ‘Latent Tuberculosis’ ‘Latent TB’ and ‘LTBI’. The literature search was conducted on May 13, 2024, and the publication period was restricted to 2014—2023. Only original research articles and review papers published in English were included, resulting in a total of 4210 relevant publications. VOSviewer software was employed to visualize the data and perform an in-depth analysis of the LTBI research field, focusing on publication trends, journal analysis, highly cited papers, international research collaboration networks, and keyword clustering. Results: Since the World Health Organization introduced its LTBI strategy in 2015, the topic has garnered sustained attention from the global academic community. From January 2014 to December 2024, we identified 4210 relevant articles, which collectively received 74324 citations, averaging 17.65 citations per article. The United States led in the number of publications (1314 articles, 31.21%), followed by China (587 articles, 13.94%). Analysis of international research cooperation networks revealed that latent tuberculosis infection research is marked by close collaboration among countries and regions, with the United States, China, the United Kingdom, India, and Italy taking leading roles. Keyword clustering indicated that the primary research focuses in this field currently include immunological mechanisms, comprehensive management, LTBI in the context of rheumatic diseases, and LTBI screening. Conclusion: This study highlights the current research landscape and future trends in the field of LTBI, offering valuable insights and references for research institutions and scholars.

Key words: Mycobacterium tuberculosis, Infection, Bibliometrics, Review literature

中图分类号:

杨逸轩, 辛继宾, 阮巧玲, 应峻, 张文宏. 文献计量视角下的结核分枝杆菌潜伏感染研究现状与展望[J]. 中国防痨杂志, 2024, 46(10): 1209-1218. doi: 10.19982/j.issn.1000-6621.20240235

Yang Yixuan, Xin Jibin, Ruan Qiaoling, Ying Jun, Zhang Wenhong. Research status and future prospects of latent tuberculosis infection from a bibliometric perspective[J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1209-1218. doi: 10.19982/j.issn.1000-6621.20240235

图/表 7

图1

表1

表2

图2

图3

表3

图4

参考文献 58

[1]	Cohen A, Mathiasen VD, Schön T, et al. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2019, 54(3):1900655. doi:10.1183/13993003.00655-2019.
[2]	Drain PK, Bajema KL, Dowdy D, et al. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev, 2018, 31(4): e00021-18. doi:10.1128/CMR.00021-18.
[3]	Furin J, Cox H, Pai M. Tuberculosis. Lancet, 2019, 393(10181):1642-1656. doi:10.1016/S0140-6736(19)30308-3. pmid: 30904262
[4]	Shah M, Dorman SE. Latent Tuberculosis Infection. N Engl J Med, 2021, 385(24):2271-2280. doi:10.1056/NEJMcp2108501.
[5]	World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. Geneva: World Health Organization, 2015.
[6]	Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol, 2022, 20(12):750-766. doi:10.1038/s41579-022-00763-4.
[7]	阮巧玲, 黄希田, 刘雪峰, 等. 免疫受损人群的潜伏性结核感染筛查和预防性治疗. 中国防痨杂志, 2017, 39(7):765-769. doi:10.3969/j.issn.1000-6621.2017.07.020.
[8]	何张玙璠, 周晶雨, 周哲, 等. 新型生物标志物组合在鉴别活动性结核与结核潜伏感染中的应用. 中华传染病杂志, 2023, 41(6):407-411. doi:10.3760/cma.j.cn311365-20221019-00438.
[9]	中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识. 中国防痨杂志, 2021, 43(9):874-878. doi:10.3969/j.issn.1000-6621.2021.09.004.
[10]	杨清銮, 阮巧玲, 张文宏. HIV感染人群结核分枝杆菌潜伏感染筛查与预防性治疗. 临床内科杂志, 2019, 36(11):729-732. doi:10.3969/j.issn.1001-9057.2019.11.004.
[11]	Pu QH, Lyu QJ, Su HY. Bibliometric analysis of scientific publications in transplantation journals from Mainland China, Japan, South Korea and Taiwan between 2006 and 2015. BMJ Open,2016, 6(8):e011623. doi:10.1136/bmjopen-2016-011623.
[12]	van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics, 2010, 84(2):523-538. doi:10.1007/s11192-009-0146-3. pmid: 20585380
[13]	刘雪立. 基于Web of Science和ESI数据库高被引论文的界定方法. 中国科技期刊研究, 2012, 23(6):975-978. doi:10.3969/j.issn.1001-7143.2012.06.015.
[14]	Esaulova E, Das S, Singh DK, et al. The immune landscape in tuberculosis reveals populations linked to disease and latency. Cell Host Microbe, 2021, 29(2):165-178. doi:10.1016/j.chom.2020.11.013. pmid: 33340449
[15]	Khader SA, Divangahi M, Hanekom W, et al. Targeting innate immunity for tuberculosis vaccination. J Clin Invest, 2019, 129(9):3482-3491. doi:10.1172/JCI128877. pmid: 31478909
[16]	Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis, 2021, 21(3):354-365. doi:10.1016/S1473-3099(20)30914-2. pmid: 33508224
[17]	Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med, 2019, 380(11): 1001-1011. doi:10.1056/NEJMoa1806808.
[18]	Ryckman T, Weiser J, Gombe M, et al. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis. Lancet Glob Health, 2023, 11(8):e1205 -e1216. doi:10.1016/S2214-109X(23)00251-6.
[19]	Velen K, Shingde RV, Ho J, et al. The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis. Eur Respir J, 2021, 58(6):2100266. doi:10.1183/13993003.00266-2021.
[20]	Roca FJ, Whitworth LJ, Redmond S, et al. TNF Induces Pathogenic Programmed Macrophage Necrosis in Tuberculosis through a Mitochondrial-Lysosomal-Endoplasmic Reticulum Circuit. Cell, 2019, 178(6):1344-1361. doi:10.1016/j.cell.2019.08.004. pmid: 31474371
[21]	Roca FJ, Whitworth LJ, Prag HA, et al. Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport. Science, 2022, 376(6600):eabh2841. doi:10.1126/science.abh2841.
[22]	Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 2019, 68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484.
[23]	Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez E, et al. Diagnosis for Latent Tuberculosis Infection: New Alternatives. Front Immunol, 2020, 11:2006. doi:10.3389/fimmu.2020.02006. pmid: 33013856
[24]	Zhou G, Luo Q, Luo S, et al. Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis, 2020, 20(12):1457-1469. doi:10.1016/S1473-3099(20)30276-0. pmid: 32673595
[25]	Hamada Y, Cirillo DM, Matteelli A, et al. Tests for tuberculosis infection: landscape analysis. Eur Respir J, 2021, 58(5):2100167. doi:10.1183/13993003.00167-2021.
[26]	Menzies D, Adjobimey M, Ruslami R, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med, 2018, 379(5):440-453. doi:10.1056/NEJMoa1714283.
[27]	Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01_E Vaccine to Prevent Tuberculosis. N Engl J Med, 2019, 381(25):2429-2439. doi:10.1056/NEJMoa1909953.
[28]	Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M.tuberculosis Infection with H4:IC 31 Vaccine or BCG Revaccination. N Engl J Med, 2018, 379(2):138-149. doi:10.1056/NEJMoa1714021.
[29]	Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med, 2015, 372(22):2127-2135. doi:10.1056/NEJMra1405427.
[30]	Alsdurf H, Hill PC, Matteelli A, et al. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis, 2016, 16(11):1269-1278. doi:10.1016/S1473-3099(16)30216-X. pmid: 27522233
[31]	Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev, 2014, 27(1):3-20. doi:10.1128/CMR.00034-13.
[32]	Koeken V, Verrall AJ, Netea MG, et al. Trained innate immunity and resistance to Mycobacterium tuberculosis infection. Clin Microbiol Infect, 2019, 25(12):1468-1472. doi:10.1016/j.cmi.2019.02.015.
[33]	Ferluga J, Yasmin H, Al-Ahdal MN, et al. Natural and trained innate immunity against Mycobacterium tuberculosis. Immunobiology, 2020, 225(3):151951. doi:10.1016/j.imbio.2020.151951.
[34]	Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis Infections. Microbiol Spectr, 2019, 7(4): 10.1128/microbiolspec.gpp3-0022-2018. doi:10.1128/microbiolspec.GPP3-0022-2018.
[35]	Chai Q, Wang L, Liu CH, et al. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis. Cell Mol Immunol, 2020, 17(9):901-913. doi:10.1038/s41423-020-0502-z.
[36]	Gideon HP, Hughes TK, Tzouanas CN, et al. Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control. Immunity, 2022, 55(5):827-846. doi:10.1016/j.immuni.2022.04.004. pmid: 35483355
[37]	Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, 2016, 387(10035):2312-2322. doi:10.1016/S0140-6736(15)01316-1. pmid: 27017310
[38]	Roy Chowdhury R, Vallania F, Yang Q, et al. A multi-cohort study of the immune factors associated with M.tuberculosis infection outcomes. Nature, 2018, 560(7720):644-648. doi:10.1038/s41586-018-0439-x.
[39]	Scriba TJ, Netea MG, Ginsberg AM. Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Semin Immunol, 2020, 50:101431. doi:10.1016/j.smim.2020.101431.
[40]	Rangaka MX, Frick M, Churchyard G, et al. Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment. Lancet Respir Med, 2023, 11(4):380-390. doi:10.1016/S2213-2600(23)00084-X. pmid: 36966794
[41]	Laghari M, Sulaiman S, Khan AH, et al. Contact screening and risk factors for TB among the household contact of children with active TB: a way to find source case and new TB cases. BMC Public Health, 2019, 19(1):1274. doi:10.1186/s12889-019-7597-0. pmid: 31533689
[42]	Li M, Guo M, Peng Y, et al. High proportion of tuberculosis transmission among social contacts in rural China: a 12-year prospective population-based genomic epidemiological study. Emerg Microbes Infect, 2022, 11(1):2102-2111. doi:10.1080/22221751.2022.2112912.
[43]	Chandrashekara S, Panchagnula R, Chennupati Y. Prevalence of LTBI in patients with autoimmune diseases and accuracy of IGRA in predicting TB relapse. Rheumatology (Oxford), 2023, 62(12):3952-3956. doi:10.1093/rheumatology/kead315.
[44]	Vanvalkenburg A, Kaipilyawar V, Sarkar S, et al. Malnutrition leads to increased inflammation and expression of tuberculosis risk signatures in recently exposed household contacts of pulmonary tuberculosis. Front Immunol, 2022, 13:1011166. doi:10.3389/fimmu.2022.1011166.
[45]	Bhargava A, Bhargava M, Meher A, et al. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. Lancet, 2023, 402(10402):627-640. doi:10.1016/S0140-6736(23)01231-X. pmid: 37567200
[46]	Shafeque A, Bigio J, Hogan CA, et al. Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?. J Clin Microbiol, 2020, 58(9): e01950-19. doi:10.1128/JCM.01950-19.
[47]	Tornheim JA, Dooley KE. Tuberculosis Associated with HIV Infection. Microbiol Spectr, 2017, 5(1). doi:10.1128/microbiolspec.TNMI7-0028-2016.
[48]	Soler-Garcia A, Gamell A, Pérez-Porcuna T, et al. Performance of QuantiFERON-TB Gold Plus assays in children and adolescents at risk of tuberculosis: a cross-sectional multicentre study. Thorax, 2022, 77(12):1193-1201. doi:10.1136/thoraxjnl-2021-217592.
[49]	Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020, 577(7788):95-102. doi:10.1038/s41586-019-1817-8.
[50]	Sudbury EL, Clifford V, Messina NL, et al. Mycobacterium tuberculosis-specific cytokine biomarkers to differentiate active TB and LTBI: A systematic review. J Infect, 2020, 81(6):873-881. doi:10.1016/j.jinf.2020.09.032. pmid: 33007340
[51]	Gong W, Wu X. Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy. Front Microbiol, 2021, 12:745592. doi:10.3389/fmicb.2021.745592.
[52]	World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[53]	Bonnet M, Vasiliu A, Tchounga BK, et al. Effectiveness of a community-based approach for the investigation and management of children with household tuberculosis contact in Cameroon and Uganda: a cluster-randomised trial. Lancet Glob Health, 2023, 11(12): e 1911-e1921. doi:10.1016/S2214-109X(23)00430-8.
[54]	Fox GJ, Nhung NV, Sy DN, et al. Household-Contact Investigation for Detection of Tuberculosis in Vietnam. N Engl J Med, 2018, 378(3):221-229. doi:10.1056/NEJMoa1700209.
[55]	Goletti D, Petrone L, Ippolito G, et al. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther, 2018, 16(6):501-512. doi:10.1080/14787210.2018.1483238. pmid: 29848120
[56]	Meije Y, Piersimoni C, Torre-Cisneros J, et al. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect, 2014, 20 Suppl 7: 89-101. doi:10.1111/1469-0691.12641.
[57]	Vasiliu A, Martinez L, Gupta RK, et al. Tuberculosis prevention: current strategies and future directions. Clin Microbiol Infect, 2023, 30(9):1123-1130. doi:10.1016/j.cmi.2023.10.023.
[58]	Harries AD, Kumar AMV, Satyanarayana S, et al. Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up. Expert Rev Respir Med, 2020, 14(2):195-208. doi:10.1080/17476348.2020.1694907.

排名	期刊	发文量(篇)	被引次数	2022年影响因子	2022年JCR分区
1	PLOS ONE	246	3749	3.7	Q2
2	INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE	161	2106	4.0	Q2
3	FRONTIERS IN IMMUNOLOGY	126	1670	7.1	Q1
4	BMC INFECTIOUS DISEASES	117	1656	3.7	Q3
5	TUBERCULOSIS	102	1874	3.2	Q3
6	CLINICAL INFECTIOUS DISEASES	91	2454	11.8	Q1
7	SCIENTIFIC REPORTS	78	864	4.6	Q2
8	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	67	1002	8.4	Q1
9	JOURNAL OF INFECTIOUS	53	1431	28.2	Q1
10	FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY	45	295	5.7	Q1

排名	期刊	被引次数	发文量(篇)	2022年影响因子	2022年JCR分区
1	PLOS ONE	3749	246	3.7	Q2
2	CLINICAL INFECTIOUS DISEASES	2454	91	11.8	Q1
3	EUROPEAN RESPIRATORY JOURNAL	2406	40	24.9	Q1
4	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	2106	161	8.4	Q1
5	LANCET INFECTIOUS DISEASES	1997	24	56.3	Q1
6	TUBERCULOSIS	1874	102	3.2	Q3
7	FRONTIERS IN IMMUNOLOGY	1670	126	7.1	Q1
8	BMC INFECTIOUS DISEASES	1656	117	3.7	Q3
9	JOURNAL OF INFECTION	1431	53	28.2	Q1
10	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE	1414	32	24.7	Q1

排名	题目	通信作者	机构/国别	年份	期刊	被引次数	文章类型
1	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection	Pai, M	McGill Univ/ Canada	2014	CLINICAL MICROBIO-LOGY REVIEWS	568	综述
2	Latent Mycobacterium tuberculosis Infection	Getahun, H	WHO/ Switzerland	2015	THE NEW ENGLAND JOURNAL OF MEDICINE	485	综述
3	Prevention of M-tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination	Hatherill, M	Univ Cape Town/South Africa	2018	THE NEW ENGLAND JOURNAL OF MEDICINE	431	论著
4	The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis	Menzies, D	Montreal Chest Inst/ Canada	2016	LANCET INFECTIOUS DISEASES	307	综述
5	The global prevalence of latent tuberculosis: a systematic review and meta-analysis	Wejse, C	Aarhus Univ Hosp/Denmark	2019	EUROPEAN RESPIRATORY JOURNAL	264	综述
6	Final Analysis of a Trial of M72/AS01_E Vaccine to Prevent Tuberculosis	Van Der Meeren, O	Glaxo Smith Kline/Belgium	2019	THE NEW ENGLAND JOURNAL OF MEDICINE	263	论著
7	Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults	Menzies, D	Montreal Chest Inst/Canada	2018	THE NEW ENGLAND JOURNAL OF MEDICINE	239	论著
8	One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis	Chaisson, RE	Johns Hopkins Univ	2019	THE NEW ENGLAND JOURNAL OF MEDICINE	196	论著

文献计量视角下的结核分枝杆菌潜伏感染研究现状与展望

Research status and future prospects of latent tuberculosis infection from a bibliometric perspective

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 7

参考文献 58

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	中国防痨协会结核病控制专业分会, 中国防痨协会青年分会, 《中国防痨杂志》编辑委员会. 中国结核病数字服药依从性技术应用指南[J]. 中国防痨杂志, 2025, 47(4): 385-397.
[2]	王颖超, 刘唯夷, 姬秀秀, 尚雪恬, 贾红彦, 张蓝月, 孙琦, 杜博平, 朱传智, 潘丽萍, 张宗德. 结核病患者外周血单个核细胞内环状RNA表达谱分析及诊断标识的鉴定[J]. 中国防痨杂志, 2025, 47(4): 460-470.
[3]	尚希钰, 张慧芳, 曹玉清, 熊一白, 纪鑫毓, 田雅欣, 李佳佳, 王倪, 马艳. 基于文献计量学的结核病中医药基础研究全球研究现状及热点分析[J]. 中国防痨杂志, 2025, 47(4): 482-497.
[4]	邱伟霞, 陈丽莉, 徐约丹, 潘宁, 邱霞霞, 郑泓, 金沈洁, 李会娟, 蒋贤高. 海分枝杆菌皮肤感染患者护理一例[J]. 中国防痨杂志, 2025, 47(4): 531-534.
[5]	中国人民解放军总医院第八医学中心结核病医学部, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会, 结核病防治分会基础和临床学部. 结核性腹膜炎多学科诊疗专家共识[J]. 中国防痨杂志, 2025, 47(3): 243-257.
[6]	李蕾蕾, 石磊, 王琳, 李洪伟, 徐立然, 逄宇, 宋言峥. HIV感染人群肺结节术后诊断为肺结核的临床特征分析[J]. 中国防痨杂志, 2025, 47(3): 266-273.
[7]	谭黄圣, 蓝志明, 付远飞, 赖居易, 冯华龙, 蒋勇, 邓鹏伟, 何升华. 颈椎布鲁氏菌感染一例[J]. 中国防痨杂志, 2025, 47(3): 380-383.
[8]	中国防痨协会《中国防痨杂志》编辑委员会首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所 Inspire⁃CODA研究组. 康替唑胺治疗结核病专家共识[J]. 中国防痨杂志, 2025, 47(2): 123-129.
[9]	《脊柱结核并发HIV/AIDS患者诊断及治疗专家共识》编写组, 中国防痨协会骨关节结核专业分会, 中国性病艾滋病防治协会艾滋病外科专业委员会, 中国西部骨结核联盟, 中国华北骨结核联盟. 脊柱结核并发HIV/AIDS患者诊断及治疗专家共识(第2版)[J]. 中国防痨杂志, 2025, 47(1): 1-11.
[10]	张国钦, 曲婷, 孟庆琳, 周林, 刘二勇. 我国结核病合并HIV/AIDS双重感染防治策略的实施进展[J]. 中国防痨杂志, 2025, 47(1): 12-17.
[11]	李福栋, 马晓雪, 周建, 王大福, 张玥颖, 龚婷婷, 饶文, 洪峰, 李世军, 李进岚. 2018—2023年贵州省利福平敏感MTB/HIV双重感染患者流行特征及治疗转归分析[J]. 中国防痨杂志, 2025, 47(1): 36-43.
[12]	刘怡, 罗瑶, 李锋. 甘草酸二铵与替比夫定联用对肺结核患者合并乙型肝炎抗病毒感染的临床疗效分析[J]. 中国防痨杂志, 2024, 46(S2): 60-61.
[13]	午水东. 舒普深联合抗生素对重症肺部感染患者的疗效研究[J]. 中国防痨杂志, 2024, 46(S2): 91-93.
[14]	张明明. 中医内科治疗肺部真菌感染的效果分析[J]. 中国防痨杂志, 2024, 46(S2): 106-108.
[15]	刘鹏, 韩萍. 杏苏止嗽汤联合呼吸导引操治疗新型冠状病毒感染轻、中型患者临床研究[J]. 中国防痨杂志, 2024, 46(S2): 162-164.